Biologic Therapy May Reshape Blood Clot Risk in Hidradenitis Suppurativa Over Time
A new retrospective study examines how venous thromboembolism risk changes over the course of biologic therapy in patients with hidradenitis ...
A new retrospective study examines how venous thromboembolism risk changes over the course of biologic therapy in patients with hidradenitis ...
A prospective cohort study found that IBD patients in endoscopic remission who report IBS-like symptoms use significantly more healthcare, particularly ...
A genetically confirmed case of Costello syndrome shows that the biologic drug dupilumab resolved severe, treatment-refractory eczema within one month, ...
A new survey of United States patients with autoimmune blistering diseases documents how insurance requirements such as prior authorization and ...
A longitudinal fluoride PET/CT study shows that spinal lesions of axial spondyloarthritis shrink and cool down during biologic treatment while ...
A new narrative review maps how methotrexate, biologics, and JAK inhibitors are transforming the management of pediatric morphea, a rare ...
A Mount Sinai retrospective analysis suggests GLP-1 receptor agonists may reduce cardiovascular risk, inflammation, and disease severity in hidradenitis suppurativa.
A 43-year cohort study of 422 Crohn's disease patients shows that 87 percent of stomas created for anorectal disease ultimately ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine